FDA authorizes COVID-19 Omicron boosters for kids as young as 5
The U.S. Food and Drug Administration on Wednesday authorized COVID-19 Omicron booster shots for children as young as five, taking an additional step to help kids stay protected against the virus.
In a statement, the FDA said it had cleared the updated booster from Pfizer and its partner BioNTech for children ages five to 11. The agency also authorized the updated booster from Moderna for children ages six to 17.
Wednesday's news marks a continuing update on the available boosters for children, as the FDA had previously cleared the Pfizer booster for people 12 and over, and the Moderna booster for people 18 and older, per The Wall Street Journal. Children ages five to 11 could have access to the Omicron boosters "in the coming days" if the shots soon receive official clearance from the U.S. Centers for Disease Control and Prevention, the Journal added.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The FDA has continued to push vaccines for kids, particularly as winter approaches. "Since children have gone back to school in person and people are resuming pre-pandemic behaviors and activities, there is the potential for increased risk of exposure to the virus that causes COVID-19," Dr. Peter Marks told the FDA. "Vaccination remains the most effective measure to prevent the severe consequences of COVID-19."
Even as the effort to vaccinate children continues, data from the American Academy of Pediatrics cited by the Journal says that just 31 percent of kids ages five to 11 have completed their primary vaccine series.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Justin Klawans has worked as a staff writer at The Week since 2022. He began his career covering local news before joining Newsweek as a breaking news reporter, where he wrote about politics, national and global affairs, business, crime, sports, film, television and other news. Justin has also freelanced for outlets including Collider and United Press International.
-
A peek inside Europe’s luxury new sleeper busThe Week Recommends Overnight service with stops across Switzerland and the Netherlands promises a comfortable no-fly adventure
-
Space data centers could be joining the orbitUnder the radar The AI revolution is going cosmic
-
Codeword: December 23, 2025The daily codeword puzzle from The Week
-
Deaths of children under 5 have gone up for the first time this centuryUnder the radar Poor funding is the culprit
-
A fentanyl vaccine may be on the horizonUnder the radar Taking a serious jab at the opioid epidemic
-
Health: Will Kennedy dismantle U.S. immunization policy?Feature ‘America’s vaccine playbook is being rewritten by people who don’t believe in them’
-
More adults are dying before the age of 65Under the radar The phenomenon is more pronounced in Black and low-income populations
-
Ultra-processed AmericaFeature Highly processed foods make up most of our diet. Is that so bad?
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
Is this the end of ultraprocessed foods?Today's Big Question California law and the MAHA movement are on the same track
